Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Trading Down 0.7% – Time to Sell?

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI)’s stock price fell 0.7% during mid-day trading on Tuesday . The company traded as low as $1.2801 and last traded at $1.33. Approximately 48,501 shares changed hands during trading, a decline of 66% from the average session volume of 141,520 shares. The stock had previously closed at $1.34.

Calidi Biotherapeutics Price Performance

The firm has a 50-day moving average of $1.79 and a 200 day moving average of $3.92. The company has a market capitalization of $3.48 million, a PE ratio of -0.02 and a beta of 1.32. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.68 and a quick ratio of 1.68.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last issued its earnings results on Thursday, August 13th. The company reported ($2.94) earnings per share for the quarter.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new stake in Calidi Biotherapeutics in the fourth quarter worth approximately $25,000. Geode Capital Management LLC raised its stake in Calidi Biotherapeutics by 41.7% during the 4th quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock valued at $49,000 after buying an additional 12,334 shares during the last quarter. Finally, DRW Securities LLC purchased a new stake in Calidi Biotherapeutics during the 4th quarter valued at $173,000. Institutional investors own 12.53% of the company’s stock.

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.